Latest Ocusciences News
Mar 22, 2023
OcuSciences Announces Publication Showing Potential to Detect Retinal Diseases with High Sensitivity Share https://eyewire.news/news/ocusciences-announces-publication-showing-potential-to-detect-retinal-diseases-with-high-sensitivity OcuSciences announced a publication in Frontiers in Ophthalmology that shows the potential to detect retinal diseases with high sensitivity. By assessing the flavoprotein fluorescence in the retina with its flagship device, the OcuMet Beacon, these findings suggest that the FPF measure can detect retinal diseases with a high degree of sensitivity. The cross-sectional observational study is led by Richard Rosen, MD, Chief of the Retina Service and Vice Chair and Director of Ophthalmology Research at New York Eye and Ear Infirmary of Mount Sinai. It includes 88 eyes, with cohorts of retinal vein occlusion (RVO), diabetic retinopathy (DR), exudative age-related macular degeneration (AMD), and central serous retinopathy (CSR). Patients were imaged with the OcuMet Beacon between October 2021 and August 2022 to capture and measure their overall FPF intensity and FPF heterogeneity. Patients in all four cohorts, which make up some of the leading causes of visual impairment worldwide, were shown to have significantly elevated FPF measures. “Similar to our prior publications in glaucoma and diabetic macular edema, these findings suggest that flavoprotein fluorescence is a robust and reliable measure when investigating retinal diseases,” said Dr. Rosen. “This further supports that FPF could become an everyday tool in the detection and monitoring of retinal disease.” “While these results pertain to four of the most common retinal diseases seen in clinical settings, we have also begun investigating inherited diseases, such as sickle cell disease, and its impact on retinal health,” said lead author Sofia Ahsanuddin, Retina Research Fellow at New York Eye and Ear Infirmary of Mount Sinai. The OcuMet Beacon is an automated, rapid retinal imager that assesses mitochondrial function by interrogating flavoproteins. The OcuMet Beacon uses specific spectral signatures and advanced software to help clinicians identify early markers of disease. Mitochondrial dysfunction has been documented as a precursor to apoptosis, or cell death, and is implicated in many retinal diseases and disorders. The OcuMet Beacon is currently being used under Institutional Review Board at New York Eye and Ear Infirmary at Mount Sinai. More in Retina
Ocusciences Frequently Asked Questions (FAQ)
Where is Ocusciences's headquarters?
Ocusciences's headquarters is located at Ann Arbor.
What is Ocusciences's latest funding round?
Ocusciences's latest funding round is Seed.
How much did Ocusciences raise?
Ocusciences raised a total of $250K.
Who are Ocusciences's competitors?
Competitors of Ocusciences include Cerapedics, eSight, Powervision, TearScience, Tandem Diabetes Care and 15 more.
Compare Ocusciences to Competitors
Realistic Eye aims to provide a more natural appearance for the 750,000 patients in the US with an artificial eye that does not dilate and therefore appears unnatural. RealisticEye achieves these results by introducing a dilating artificial eye.
eSight creates electronic glasses that restore or enhance sight for individuals living with vision loss. Worn comfortably like a normal pair of glasses or with prescription lenses built-in, they allow a person with low vision to see in virtually the same manner as someone who is fully-sighted can. The company's SPEX enhances vision for precision tasks, allowing users to pan and zoom the real world or streamed images, and brings critical information to the point of task without overwriting or obstructing natural vision for full situational awareness and mobility.
Mystic Pharmaceuticals develops devices that deliver drugs through the nose to the eyes.
AnaeMedia is a socio-technological initiative. The company have developed a prick-less anaemia scanner that can measure HB levels and help diagnose anaemia by referring to an accompanying simple chart.
Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.
Biopticon Corporation is aimed to develop medical diagnostic devices using laser, photonics and image processing based technologies.